PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

PRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) event to discuss the pathology and growing prevalence of HPV16-positive head and neck squamous cell carcinoma (“HNSCC") as well as the Company’s upcoming VERSATILE-003 Phase 3 clinical trial of Versamune^® HPV + pembrolizumab for first-line treatment of recurrent and/or metastatic HPV16-positive HNSCC.

Read more at globenewswire.com